Endoscopic approach to achalasia

Area of Science:

• Gastroenterology
• Esophageal Motility Disorders
• Endoscopic Therapeutics

Background:

• Achalasia is a primary esophageal motor disorder of unknown etiology.
• Current treatments aim to reduce lower esophageal sphincter (LES) pressure, offering palliative relief.
• Established endoscopic options include pneumatic dilation (PD) and botulinum toxin (BT) injection.

Purpose of the Study:

• To compare the long-term efficacy and safety of established and emerging endoscopic treatments for achalasia.
• To identify predictors of successful treatment response.
• To evaluate the role of endoscopy in achalasia management.

Main Methods:

• Review of established endoscopic therapies: pneumatic dilation (PD) and botulinum toxin (BT) injection.
• Comparison of PD and BT efficacy, including long-term outcomes and recurrence rates.
• Discussion of emerging techniques like peroral endoscopic myotomy (POEM) and self-expanding stents.
• Analysis of predictors for PD success and complication rates (e.g., esophageal perforation).

Main Results:

• Botulinum toxin (BT) shows poor long-term success, with high recurrence rates within 24 months.
• Pneumatic dilation (PD) provides sustained symptom relief in 40%-60% of patients for over 10 years, with up to 90% achieving remission with repeat treatments.
• PD efficacy in patients over 40 years old is comparable to surgery.
• PD carries a 2%-3% risk of esophageal perforation.

Conclusions:

• Pneumatic dilation (PD) is a highly effective long-term endoscopic treatment for achalasia, particularly in patients over 40.
• While BT injections offer short-term relief, their long-term efficacy is limited.
• Emerging techniques like POEM require further investigation for long-term outcomes and safety.
• Endoscopy is crucial for both diagnosis and surveillance in achalasia management.